
-
Rahm out to break 2025 win drought ahead of US PGA Championship
-
Japan tariff envoy departs for round two of US talks
-
Djurgarden eyeing Chelsea upset in historic Conference League semi-final
-
Haliburton leads comeback as Pacers advance, Pistons stay alive
-
Bunker-cafe on Korean border paints image of peace
-
Tunics & turbans: Afghan students don Taliban-imposed uniforms
-
Asian markets struggle as trade war hits China factory activity
-
Norwegian success story: Bodo/Glimt's historic run to a European semi-final
-
Spurs attempt to grasp Europa League lifeline to save dismal season
-
Thawing permafrost dots Siberia with rash of mounds
-
S. Korea prosecutors raid ex-president's house over shaman probe: Yonhap
-
Filipino cardinal, the 'Asian Francis', is papal contender
-
Samsung Electronics posts 22% jump in Q1 net profit
-
Pietro Parolin, career diplomat leading race to be pope
-
Nuclear submarine deal lurks below surface of Australian election
-
China's manufacturing shrinks in April as trade war bites
-
Financial markets may be the last guardrail on Trump
-
Swedish journalist's trial opens in Turkey
-
Kiss says 'honour of a lifetime' to coach Wallabies at home World Cup
-
US growth figure expected to make for tough reading for Trump
-
Opposition leader confirmed winner of Trinidad elections
-
Snedeker, Ogilvy to skipper Presidents Cup teams: PGA Tour
-
Win or bust in Europa League for Amorim's Man Utd
-
Trump celebrates 100 days in office with campaign-style rally
-
Top Cuban dissidents detained after court revokes parole
-
Arteta urges Arsenal to deliver 'special' fightback against PSG
-
Trump fires Kamala Harris's husband from Holocaust board
-
Pakistan says India planning strike as tensions soar over Kashmir attack
-
Weinstein sex attack accuser tells court he 'humiliated' her
-
France accuses Russian military intelligence over cyberattacks
-
Global stocks mostly rise as Trump grants auto tariff relief
-
Grand Vietnam parade 50 years after the fall of Saigon
-
Trump fires ex first gentleman Emhoff from Holocaust board
-
PSG 'not getting carried away' despite holding edge against Arsenal
-
Cuban dissidents detained after court revokes parole
-
Sweden stunned by new deadly gun attack
-
BRICS blast 'resurgence of protectionism' in Trump era
-
Trump tempers auto tariffs, winning cautious praise from industry
-
'Cruel measure': Dominican crackdown on Haitian hospitals
-
'It's only half-time': Defiant Raya says Arsenal can overturn PSG deficit
-
Dembele sinks Arsenal as PSG seize edge in Champions League semi-final
-
Les Kiss to take over Wallabies coach role from mid-2026
-
Real Madrid's Rudiger, Mendy and Alaba out injured until end of season
-
US threatens to quit Russia-Ukraine effort unless 'concrete proposals'
-
Meta releases standalone AI app, competing with ChatGPT
-
Zverev crashes as Swiatek scrapes into Madrid Open quarter-finals
-
BRICS members blast rise of 'trade protectionism'
-
Trump praises Bezos as Amazon denies plan to display tariff cost
-
France to tax small parcels from China amid tariff fallout fears
-
Hong Kong releases former opposition lawmakers jailed for subversion

The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
P.Staeheli--VB